Fragrance Allergens 2025+: What's Changing and How to Prepare

Fragrance sells product, but it also drives some of the most complex labelling and formulation work you'll do in 2025 and beyond. Europe has expanded the list of fragrance allergens that must be named on labels when present above set thresholds, Great Britain hasn't (yet) mirrored those changes, and the U.S. is moving toward its own disclosure rule under MoCRA.

Read on for a clear, practical path through the moving parts so you can plan reformulation, labelling, and artwork updates with confidence.

Applying Cosmetic Products to the Skin.

The European Shift: What's in Scope and When

Under Regulation (EU) 2023 / 1545, the familiar "26 allergens" paradigm is over. The amended Annex III to Regulation (EC) 1223 / 2009 now captures dozens of additional individual fragrance allergens and several natural complex substances (NCS) (e.g., certain essential oils) that must be declared by specific INCI names when they exceed:

• ≥ 0.001% in leave-on products, and

• ≥ 0.01% in rinse-off products.

Two transition milestones drive your planning:

• 31 July 2026 - No more first placing on the EU market of non-compliant products.

• 31 July 2028 - End of making available on the market (sell-through). Non-compliant stock must be gone.

Those dates govern all language and pack sizes, so coordinate centrally and execute locally.

Great Britain and Northern Ireland

• Great Britain (England, Scotland, Wales): As of 2025, GB had not yet implemented the EU's expanded allergen list. Expect consultation / updates via OPSS. Plan for potential dual artwork (EU vs GB) or use pan-EU packs with GB over-labels only if / when permissible.

  
  

• Northern Ireland: Follows EU cosmetics law, treat NI like EU for allergens and timing.

United States (MoCRA)

MoCRA requires FDA to establish a U.S. fragrance-allergen labelling list by regulation. As of 2025, FDA had not finalised that last; the proposal is pending.

The FDA must consider international approaches, so preparing against the EU's expanded set is sensible, but avoid assuming a verbatim match. Build flexibility into specs and label templates so you can pivot when FDA publishes.

A Practical Preparation Plan

Start with your current portfolio and work forward, sequencing high-volume and high-risk items first.

1. Audit, Map, and Gap-Assess

   Compile full fragrance disclosures (IFRA Certificates + 100% ingredient breakdowns, not just "Q.C. compliant"). Map every listed EU Annex III allergen and NCS to your formulas and calculate finished-product concentrations against the 0.001% / 0.01% thresholds. Flag SKUs with allergens above thresholds and SKUs clear of disclosure.

   
   

2. Decide: Label-Declare or Reformulate

   For each SKU, weigh commercial impact versus technical effort. Options include:

   - Label-declare the required allergens and proceed.

   - Reformulate (e.g., lower a component, swap to an alternative) to fall below thresholds or eliminate the allergen.

   - Create variant strategies (EU vs GB vs U.S.) where the market mix justifies differentiated formulas.

3. Lock Your Nomenclature

   EU requires specific INCI names (including listed natural complex substances). Ensure your artwork uses the correct entries from Annex III, no umbrella terms. Where an NCS contains multiple listed allergens and the sum triggers thresholds, multiple declarations may be required.

   
   

4. Artwork and Pack Strategy

   Build a single master artwork brief covering:

   - Ingredient list updates (alphabetical INCI, allergens appended per EU rules).

   - Small packs: validate legibility; if you use peel-back labels, confirm adhesive / print specs and line capability.

   - Digital assets and e-commerce listings: keep website and retailer copy synchronised with on-pack INCI.

   
   

5. Claims and Substantiation

   Recheck "hypoallergenic", "for sensitive skin", "fragrance-free", or "clean" claims. If allergens appear on label (even below threshold in some markets), claims may need tightening or substantiation refresh. Update your Product Information File (PIF) and Cosmetic Product Safety Report (CPSR) with the new composition, exposure estimates, and any human data.

   
   

6. Supply Chain and QC Controls

   Extend requirements into quality agreements with fragrance houses:

   - Provide timely, complete disclosure for every fragrance batch and variant.

   - Notify of composition changes under change control.

   - Confirm analytical methods (where used) can detect declared allergens / NCS at relevant limits. Strengthen incoming review of IFRA documents and allergen breakdowns; set effective dates tied to EU milestones.

   
   

7. Country Cut-Overs and Sell-Downs

   - EU / NI: plan production switch-overs so EU stock made after 31 July 2026 is compliant; model sell-down to clear all legacy stock by 31 July 2028.

   - GB: maintain a watch brief; pre-build label variants but avoid printing at scale until policy is firm.

   - US: keep editable placeholders in label templates for future FDA allergen names.

Managing Reformulation Without Losing Your Brand's Signature

If you change fragrance to avoid declarations (or to reduce the list length), protect the consumer experience:

• Run triangle tests and consumer sniff panels to confirm parity.

• Check stability (odour, colour, viscosity) and compatibility (pack, valves, wicks).

• Re-verify IFRA category limits and any sensory claims.

Document all changes through change control, and reflect them in CPSRs and PIFs.

Where This Leaves You

Across the EU, the direction is settled: more allergens must be named, on short timelines that will stress supply chain, labelling, and regulatory review. GB may follow with its own timetable; the U.S. will likely set a federal list under MoCRA.

The winning posture is consistent: know your composition, model your thresholds, plan your labels, and keep optionality so you can adapt per market without repeated rework. Teams that start now will avoid last-minute scrambles, reduce write-offs, and protect both consumer trust and brand equity.

📌Ready for change?

If you'd like expert help planning your allergen transition, portfolio mapping, reformulation options, PIF updates, Pharmalliance Consulting Ltd can support you.

Our cGMP Cosmetics Compliance Program also gives your team the practical tools to manage regulatory change with confidence; from Annex III allergens to MoCRA readiness.

Want the playbook and a partner to execute it? Let's talk today!